

# ONUREG (azacitidine)

#### **Pre - PA Allowance**

None

## **Prior-Approval Requirements**

Age 18 years of age or older

#### Diagnosis

The patient must have the following:

- 1. Acute myeloid leukemia (AML) with **ONE** of the following:
  - a. Patient has achieved first complete remission (CR) following intensive induction chemotherapy
  - b. Patient has achieved complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy

#### **AND ALL** of the following:

- 1. Patient is not able to complete intensive curative therapy
- Prescriber agrees to monitor complete blood count (CBC) and absolute neutrophil count (ANC) for myelosuppression and modify the dosage if needed
- 3. Female patients of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Onureg and for 6 months after the last dose
- Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Onureg and for 3 months after the last dose

## **Prior - Approval Limits**

- **Quantity** 42 tablets per 84 days
- **Duration** 12 months

## Prior – Approval Renewal Requirements

Age 18 years of age or older

Diagnosis



# ONUREG (azacitidine)

The patient must have the following:

1. Acute myeloid leukemia (AML)

#### AND ALL of the following:

- 1. NO disease progression or unacceptable toxicity
- Prescriber agrees to monitor complete blood count (CBC) and absolute neutrophil count (ANC) for myelosuppression and modify the dosage if needed
- 3. Female patients of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Onureg and for 6 months after the last dose
- Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Onureg and for 3 months after the last dose

### Prior - Approval Renewal Limits

Same as above